Literature DB >> 6547348

Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy.

S Viganò, P M Mannucci, S Solinas, B Bottasso, G Mariani.   

Abstract

Changes in protein C antigen (PC:Ag) have been compared with those in factor II, VII, IX and X antigens (II:Ag; VII:Ag; IX:Ag and X:Ag) in 10 patients starting on oral anticoagulant therapy with warfarin, monitored with thrombotest. Between days 0 and 3 of therapy, PC:Ag decreased at the same rate as VII:Ag, whilst IX:Ag, X:Ag and II:Ag decreased at progressively slower rates. On days 15 and 21, clotting proteins and PC:Ag did not differ significantly. Before and after warfarin, PC:Ag had the same mobility on crossed immunoelectrophoresis in Ca2+-free agarose gel; with Ca2+, a protein with faster anodal mobility appeared on day 1 and became maximal 5 d after warfarin was started. These findings indicate that the rate of PC decrease is closer to that of factor VII than those of factors IX, X and II, and that an abnormal PC with poor Ca2+-binding properties appears soon after treatment is started. The early decrease in the physiological inactivator (i.e. PC) might contribute to the poor antithrombotic efficacy of anticoagulant therapy during the first days.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547348

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

2.  A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure.

Authors:  Tammy J Bungard; Jay Mutch; Bruce Ritchie
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

3.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Authors:  I A Choonara; R G Malia; B P Haynes; C R Hay; S Cholerton; A M Breckenridge; F E Preston; B K Park
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

4.  Protein C antigen in prothrombin complex concentrates: content, recovery and half life.

Authors:  H Riess; T Binsack; E Hiller
Journal:  Blut       Date:  1985-05

5.  Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.

Authors:  S Vigano D'Angelo; P C Comp; C T Esmon; A D'Angelo
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

Review 6.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 7.  Clinical relevance of protein C.

Authors:  I Pabinger
Journal:  Blut       Date:  1986-08

8.  Anticoagulation after cardioembolic stroke: to bridge or not to bridge?

Authors:  Hen Hallevi; Karen C Albright; Sheryl Martin-Schild; Andrew D Barreto; Sean I Savitz; Miguel A Escobar; Nicole R Gonzales; Elizabeth A Noser; Kachi Illoh; James C Grotta
Journal:  Arch Neurol       Date:  2008-07-14

9.  A simplified functional assay for protein C in plasma samples.

Authors:  W Thiel; K T Preissner; U Delvos; G Müller-Berghaus
Journal:  Blut       Date:  1986-03

10.  Detection of protein C activation in humans.

Authors:  K A Bauer; B L Kass; D L Beeler; R D Rosenberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.